ImmunityBio, Inc. (NASDAQ:IBRX) was among the stocks on which Jim Cramer commented, as he emphasized that SpaceX investors ...
ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 10 Best Performing Growth Stocks So Far in 2026. On June 1, ImmunityBio, Inc. (NASDAQ:IBRX) reported that it presented two research posters and one online ...
If you have suffered a loss on your ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ:IBRX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or ...
https://www.ktmc.com/ibrx-immunitybio-inc-class-action-lawsuit?utm_source=NewMediaWire&utm_medium=pressrelease&utm_campaign=ibrx&mktm=PR There is no cost or ...
Law Offices of Howard G. Smith announces an investigation on behalf of ImmunityBio, Inc. (“ImmunityBio” or the “Company”) (NASDAQ: IBRX) investors concerning the Company’s possible violations of ...
SAN DIEGO, April 8, 2026 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 ...
SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities ...
What Is This Lawsuit About? The lawsuit alleges that (1) Defendant Patrick Soon-Shiong, the Company’s Executive Chairman of the Board, materially overstated the capabilities of Anktiva, an ...
Whales with a lot of money to spend have taken a noticeably bearish stance on ImmunityBio. Looking at options history for ImmunityBio (NASDAQ:IBRX) we detected 21 trades. If we consider the specifics ...
On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying CAVA Group, Inc. CAVA. “I think it's the best of the new ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...
Shares of cancer and infectious disease therapy developer ImmunityBio, Inc. (NASDAQ: IBRX), spiked 34% higher as of 1 p.m. ET on Friday and are now up a staggering 127% this week after an incredible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results